Floatz Rating
B56/100
Confidence
Indicative
Sponsor
Merck Sharp & Dohme LLC
Modality
antibody_drug_conjugate
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07060807CT.gov A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) | — | Recruiting | — | — | — |
NCT07030569CT.gov RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study | — | Recruiting | — | — | — |
NCT05113251CT.gov Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT01042379CT.gov I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Trastuzumab Deruxtecan (this asset) | Merck Sharp & Dohme LLC | P3 | B · 56 |
| Cyclophosphamide | Merck Sharp & Dohme LLC | P4 | BB |
| Tamoxifen | Eli Lilly and Company | P3 | BB |
| Exemestane | Fujian Cancer Hospital | P4 | BB |
| Adriamycin | Merck Sharp & Dohme LLC | P4 | BB |
| Docetaxel | Universitas Airlangga | P4 | BB |
| Letrozole | Fujian Cancer Hospital | P4 | BB |
| Palbociclib | Eli Lilly and Company | P4 | BB |
| Microporous Polysaccharide Hemospheres | Fundación para la Investigación del Hospital Clínico de Valencia | P4 | BB |
+42 more in the Breast Neoplasm cohort
Other indications for Trastuzumab Deruxtecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 75 |
| Breast Cancer | — | P4 | BB · 66 |
| Metastatic Malignant Neoplasm In The Brain | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Trastuzumab Deruxtecan in Breast Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/trastuzumab-deruxtecan-breast-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →